These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27465278)

  • 1. hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
    Fürtjes G; Köchling M; Peetz-Dienhart S; Wagner A; Heß K; Hasselblatt M; Senner V; Stummer W; Paulus W; Brokinkel B
    J Neurooncol; 2016 Oct; 130(1):79-87. PubMed ID: 27465278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
    Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
    Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
    Stögbauer L; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
    Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
    J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade.
    Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
    Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
    Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
    Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q.
    Bello MJ; Amiñoso C; Lopez-Marin I; Arjona D; Gonzalez-Gomez P; Alonso ME; Lomas J; de Campos JM; Kusak ME; Vaquero J; Isla A; Gutierrez M; Sarasa JL; Rey JA
    Acta Neuropathol; 2004 Nov; 108(5):413-21. PubMed ID: 15365725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
    Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.
    Miyake Y; Adachi JI; Suzuki T; Mishima K; Araki R; Mizuno R; Nishikawa R
    J Neurooncol; 2019 Jan; 141(1):131-138. PubMed ID: 30392088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hTERT promoter methylation in pituitary adenomas.
    Köchling M; Ewelt C; Fürtjes G; Peetz-Dienhart S; Koos B; Hasselblatt M; Paulus W; Stummer W; Brokinkel B
    Brain Tumor Pathol; 2016 Jan; 33(1):27-34. PubMed ID: 26390879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
    Goutagny S; Nault JC; Mallet M; Henin D; Rossi JZ; Kalamarides M
    Brain Pathol; 2014 Mar; 24(2):184-9. PubMed ID: 24261697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear.
    Vogels R; Macagno N; Griewank K; Groenen P; Verdijk M; Fonville J; Kusters B; ; ; Figarella-Branger D; Wesseling P; Bouvier C; Flucke U
    Acta Neuropathol; 2019 Apr; 137(4):679-682. PubMed ID: 30761420
    [No Abstract]   [Full Text] [Related]  

  • 17. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo.
    Cabuy E; de Ridder L
    Virchows Arch; 2001 Aug; 439(2):176-84. PubMed ID: 11561758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of the hTERT promoter: a novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids.
    Bougel S; Lhermitte B; Gallagher G; de Flaugergues JC; Janzer RC; Benhattar J
    Clin Cancer Res; 2013 Apr; 19(8):2216-23. PubMed ID: 23444211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [DNA methylation of human telomerase reverse transcriptase promoter region in human ameloblastoma].
    Zhong M; Yan Y; Wang J; Liu J; Li L; Gong YB
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2007 May; 42(5):304-7. PubMed ID: 17686286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.